Contact Us
Drug Search Results
More Filters [+]

UCN-01

Alternative Names: ucn-01, 7-hydroxystaurosporine
Latest Update: 2024-02-06
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: PKC Inhibitor,CDK Inhibitor,PK Inhibitor,CHK1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for UCN-01

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: T-Cell Lymphoma|Fallopian Tube Cancer|Large-Cell Anaplastic Lymphoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Kidney Cancer|Peritoneal Cancer|Pancreatic Cancer|Ovarian Cancer|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Melanoma

Phase 1: Acute Myeloid Leukemia|Paranasal Sinus Diseases|Ovarian Diseases|Germinoma|Oncology Solid Tumor Unspecified|Esophageal Cancer|Uterine Cervical Diseases|Bile Duct Diseases|Adenocarcinoma|Breast Cancer|Verrucous Carcinoma|Salivary Gland Cancer|Pancreatic Cancer|Breast Diseases|Anus Cancer|Myelodysplastic Syndrome|Preleukemia|Lymphoma|Prostate Cancer|Leukemia|Salivary Gland Diseases|Cholangiocarcinoma|Nasopharyngeal Diseases|Basal Cell Carcinoma|Sarcoma, Endometrial Stromal|Intestinal Diseases|Anal Gland Cancer|Rectal Diseases|Head and Neck Cancer|Cervical Cancer|Border Disease|Endometrial Stromal Tumors|Embryonal Carcinoma|Brenner Tumor|Carcinoid Tumor|Stomach Diseases|Esophageal Diseases|Nasopharyngeal Cancer|Ovarian Cancer|Gallbladder Diseases|Endometrial Cancer|Bile Duct Cancer|Gastrointestinal Stromal Tumors|Pancreatic Cyst|Mucoepidermoid Tumor|Liver Cancer|Papilloma, Inverted|Granuloma, Lethal Midline|Adenoid Cystic Carcinoma|Uterine Diseases|Leiomyosarcoma|Colorectal Cancer|Dermoid Cyst|Paranasal Sinus Cancer|Colonic Diseases|Anus Diseases|Oropharyngeal Cancer|Mucoepidermoid Carcinoma|Prostatic Diseases|Malignant Carcinoid Syndrome|Uterine Cancer|Esophageal Cyst|Gastrointestinal Cancer|Laryngeal Cancer|Olfactory Esthesioneuroblastoma|Gallbladder Cancer|Acute Erythroblastic Leukemia|Myelodysplastic-Myeloproliferative Diseases|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer|Granuloma, Laryngeal|Acute Lymphoid Leukemia|Blast Crisis|Chronic Myelomonocytic Leukemia|Acute Promyelocytic Leukemia|Myeloproliferative Disorders|Chronic Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Adult T-Cell Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Lung Cancer|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Myeloid, Accelerated Leukemia|Acute Monocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Peritoneal Cancer|Fallopian Tube Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PMH-PHL-005

P1

Completed

Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer

2013-06-01

NCI-2009-00149

P1

Completed

Chronic Lymphoid Leukemia|Myeloproliferative Disorders|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Acute Erythroblastic Leukemia|Myelodysplastic Syndrome|Acute Promyelocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Blast Crisis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia|Adult T-Cell Leukemia-Lymphoma|Myeloid, Accelerated Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Preleukemia|Myelodysplastic-Myeloproliferative Diseases

2012-05-01

04-C-0173

P2

Terminated

T-Cell Lymphoma|Large-Cell Anaplastic Lymphoma

2011-09-27

NCI-2009-00019

P1

Completed

Embryonal Carcinoma|Non-Small-Cell Lung Cancer|Carcinoid Tumor|Brenner Tumor|Esophageal Cancer|Uterine Cervical Diseases|Nasopharyngeal Diseases|Cholangiocarcinoma|Salivary Gland Cancer|Nasopharyngeal Cancer|Olfactory Esthesioneuroblastoma|Laryngeal Cancer|Gastrointestinal Cancer|Esophageal Cyst|Stomach Diseases|Esophageal Diseases|Verrucous Carcinoma|Pancreatic Cyst|Bile Duct Diseases|Squamous Cell Carcinoma|Gastrointestinal Stromal Tumors|Mucoepidermoid Tumor|Ovarian Cancer|Sarcoma, Endometrial Stromal|Oropharyngeal Cancer|Mucoepidermoid Carcinoma|Basal Cell Carcinoma|Anus Diseases|Colorectal Cancer|Adenoid Cystic Carcinoma|Uterine Diseases|Leiomyosarcoma|Anal Gland Cancer|Colonic Diseases|Intestinal Diseases|Dermoid Cyst|Paranasal Sinus Cancer|Gallbladder Cancer|Granuloma, Lethal Midline|Papilloma, Inverted|Uterine Cancer|Gallbladder Diseases|Endometrial Cancer|Liver Cancer|Adenocarcinoma|Endometrial Stromal Tumors|Border Disease|Germinoma|Ovarian Diseases|Cervical Cancer|Head and Neck Cancer|Granuloma, Laryngeal|Prostatic Diseases|Bile Duct Cancer|Paranasal Sinus Diseases|Anus Cancer|Salivary Gland Diseases|Breast Diseases|Lymphoma|Pancreatic Cancer|Malignant Carcinoid Syndrome|Triple Negative Breast Cancer|Prostate Cancer|Rectal Diseases

2011-01-01

Recent News Events

Date

Type

Title

02/06/2024

PubMed

 Selective inhibition of DNA ligase IV provides additional efficacy to the treatment of anaplastic thyroid cancer.

01/17/2024

PubMed

 Pyrin Inflammasome Activation Defines Colchicine-Responsive SURF Patients from FMF and Other Recurrent Fevers.

11/02/2023

PubMed

 Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions